Premas Biotech

Bronze Sponsor

At Premas Biotech, we are a platform-driven biotechnology company delivering advanced research and development solutions to the global vaccine ecosystem. Our focus is on innovation, translational science, and strategic collaboration to advance next-generation vaccine technologies targeting emerging and high-burden infectious diseases.

Our scientific differentiation is anchored in our proprietary D-CRYPT™ yeast-based platform, engineered to enable efficient expression of difficult-to-produce and membrane-associated antigens. Through this system, we develop structurally authentic Virus-Like Particles (VLPs), multi-antigen constructs, and RNA-enabled vaccine formats. The platform is designed to compress development timelines, enhance antigen integrity, and establish scalable, cost-efficient manufacturing pathways.

We integrate expertise across immunology, molecular biology, strain engineering, and bioprocess optimization to design vaccine candidates that are robust, stable, and commercially viable. Our integrated infrastructure supports rapid construct design, expression screening, analytical characterization, and downstream process development—creating a streamlined pathway from discovery through preclinical validation.

Beyond internal platform advancement, we engage in targeted scientific and commercial collaborations with biotechnology companies, vaccine developers, animal health organizations, and government stakeholders. We operate through structured co-development programs, CDMO-led process development, and phased licensing models built around our D-CRYPT™ platform.

Our partnerships typically include antigen design and optimization, strain engineering, upstream and downstream process development, analytical method alignment, and scalable yeast-based manufacturing strategies. Where required, we support clone transfer, process documentation, batch protocol standardization, and technical training to enable localized production.

Through this model, we help partners de-risk complex antigen expression, shorten development timelines, and establish commercially viable, regionally adaptable manufacturing frameworks for both human and veterinary vaccine programs.

With a science-led foundation and commercialization-focused execution strategy, we position ourselves as a strategic partner for organizations seeking differentiated vaccine platforms, accelerated development cycles, and globally deployable solutions.

website